DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype.
作者信息
Nangalia Jyoti, Nice Francesca L, Wedge David C, Godfrey Anna L, Grinfeld Jacob, Thakker Clare, Massie Charlie E, Baxter Joanna, Sewell David, Silber Yvonne, Campbell Peter J, Green Anthony R
机构信息
Department of Haematology, Cambridge Institute for Medical Research and Wellcome Trust/MRC Stem Cell Institute, University of Cambridge, Cambridge, UK Department of Haematology, Addenbrooke's Hospital, Cambridge, UK Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK.
Department of Haematology, Cambridge Institute for Medical Research and Wellcome Trust/MRC Stem Cell Institute, University of Cambridge, Cambridge, UK.
出版信息
Haematologica. 2015 Nov;100(11):e438-42. doi: 10.3324/haematol.2015.129510. Epub 2015 Aug 6.
Abstract
摘要
相似文献
1
DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype.DNA甲基转移酶3A（DNMT3A）突变在骨髓增殖性肿瘤患者中可早发或晚发，且突变顺序会影响表型。
Haematologica. 2015 Nov;100(11):e438-42. doi: 10.3324/haematol.2015.129510. Epub 2015 Aug 6.
2
Mutation analysis of JAK2V617F, FLT3-ITD, NPM1, and DNMT3A in Chinese patients with myeloproliferative neoplasms.中国骨髓增殖性肿瘤患者中JAK2V617F、FLT3-ITD、NPM1和DNMT3A的突变分析
Biomed Res Int. 2014;2014:485645. doi: 10.1155/2014/485645. Epub 2014 May 11.
3
DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms.原发性骨髓纤维化、慢性粒单核细胞白血病及骨髓增殖性肿瘤晚期阶段中DNMT3A的突变分析
Leukemia. 2011 Jul;25(7):1219-20. doi: 10.1038/leu.2011.82. Epub 2011 Apr 26.
4
JAK2 haplotype 46/1 and JAK2 V617F allele burden in MPN: New evidence against the "hypermutability" hypothesis?骨髓增殖性肿瘤中JAK2单倍型46/1及JAK2 V617F等位基因负荷：反对“高突变性”假说的新证据？
Int J Lab Hematol. 2018 Feb;40(1):e8-e10. doi: 10.1111/ijlh.12765. Epub 2017 Nov 14.
5
Alterations to in Hematologic Malignancies.血液系统恶性肿瘤中的 改变。
Cancer Res. 2021 Jan 15;81(2):254-263. doi: 10.1158/0008-5472.CAN-20-3033. Epub 2020 Oct 21.
6
Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.骨髓增殖性肿瘤中 ASXL1、CBL、DNMT3A、IDH1、IDH2、JAK2、MPL、NF1、SF3B1、SUZ12 和 TET2 的突变分析。
Genes Chromosomes Cancer. 2012 Aug;51(8):743-55. doi: 10.1002/gcc.21960. Epub 2012 Apr 9.
7
Landscape of biallelic DNMT3A mutant myeloid neoplasms.双等位基因突变 DNMT3A 骨髓增生性肿瘤的全景图。
J Hematol Oncol. 2024 Sep 27;17(1):87. doi: 10.1186/s13045-024-01607-9.
8
[Relationship between DTA Mutations and Thromboembolism in Patients with Myeloproliferative Neoplasms].[骨髓增殖性肿瘤患者中DTA突变与血栓栓塞的关系]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Jun;32(3):819-824. doi: 10.19746/j.cnki.issn.1009-2137.2024.03.025.
9
DNA methyltransferases in hematological malignancies.血液恶性肿瘤中的 DNA 甲基转移酶。
J Genet Genomics. 2020 Jul 20;47(7):361-372. doi: 10.1016/j.jgg.2020.04.006. Epub 2020 Jul 24.
10
Myeloproliferative neoplasms with a low (<5%) CALR mutation allele burden.伴有低（<5%）CALR突变等位基因负荷的骨髓增殖性肿瘤
Blood Cells Mol Dis. 2021 Sep;90:102593. doi: 10.1016/j.bcmd.2021.102593. Epub 2021 Jun 29.
引用本文的文献
1
IMOP-Cancer: identifying mutation order pairs impacting cancer phenotypes.IMOP-癌症：识别影响癌症表型的突变顺序对。
Brief Bioinform. 2025 Jul 2;26(4). doi: 10.1093/bib/bbaf362.
2
Treatment of V617F-positive primary myelofibrosis and advanced chronic myelogenous leukemia with ruxolitinib and flumatinib: a case report.用芦可替尼和氟马替尼治疗V617F阳性原发性骨髓纤维化和晚期慢性粒细胞白血病：病例报告
Ann Med Surg (Lond). 2025 Feb 28;87(3):1750-1754. doi: 10.1097/MS9.0000000000003075. eCollection 2025 Mar.
3
DNMT3A regulates murine megakaryocyte-biased hematopoietic stem cell fate decisions.DNMT3A调控小鼠巨核细胞偏向性造血干细胞的命运决定。
Blood Adv. 2025 May 13;9(9):2285-2299. doi: 10.1182/bloodadvances.2024015061.
4
Biological Markers of Myeloproliferative Neoplasms in Children, Adolescents and Young Adults.儿童、青少年和青年骨髓增殖性肿瘤的生物标志物
Cancers (Basel). 2024 Dec 8;16(23):4114. doi: 10.3390/cancers16234114.
5
Pathogenesis and management of high molecular risk myeloproliferative neoplasms.高危分子骨髓增殖性肿瘤的发病机制与管理
Haematologica. 2025 Apr 1;110(4):863-876. doi: 10.3324/haematol.2023.283987. Epub 2024 Dec 5.
6
Initiating-clone analysis in patients with acute myeloid leukemia secondary to essential thrombocythemia.继发于原发性血小板增多症的急性髓系白血病患者的起始克隆分析。
Sci Rep. 2024 Jul 10;14(1):15906. doi: 10.1038/s41598-024-66461-8.
7
Genomic evolution shapes prostate cancer disease type.基因组进化塑造前列腺癌疾病类型。
Cell Genom. 2024 Mar 13;4(3):100511. doi: 10.1016/j.xgen.2024.100511. Epub 2024 Feb 29.
8
Order-of-Mutation Effects on Cancer Progression: Models for Myeloproliferative Neoplasm.突变顺序对癌症进展的影响：骨髓增殖性肿瘤模型。
Bull Math Biol. 2024 Feb 16;86(3):32. doi: 10.1007/s11538-024-01257-5.
9
Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.骨髓纤维化的分子遗传学特征：对诊断、预后及治疗进展的意义
Cancers (Basel). 2024 Jan 25;16(3):514. doi: 10.3390/cancers16030514.
10
DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor in Polycythemia Vera Patients: An Observational Study.DNMT3A/TET2/ASXL1 基因突变是原发性血小板增多症患者独立于年龄的血栓风险因素：一项观察性研究。
Thromb Haemost. 2024 Jul;124(7):669-675. doi: 10.1055/a-2239-9265. Epub 2024 Jan 8.
本文引用的文献
1
Effect of mutation order on myeloproliferative neoplasms.突变顺序对骨髓增殖性肿瘤的影响。
N Engl J Med. 2015 Feb 12;372(7):601-612. doi: 10.1056/NEJMoa1412098.
2
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.从血液DNA序列推断克隆性造血与血癌风险。
N Engl J Med. 2014 Dec 25;371(26):2477-87. doi: 10.1056/NEJMoa1409405. Epub 2014 Nov 26.
3
Age-related clonal hematopoiesis associated with adverse outcomes.与不良预后相关的年龄相关性克隆性造血。
N Engl J Med. 2014 Dec 25;371(26):2488-98. doi: 10.1056/NEJMoa1408617. Epub 2014 Nov 26.
4
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.急性白血病中白血病前造血干细胞的鉴定。
Nature. 2014 Feb 20;506(7488):328-33. doi: 10.1038/nature13038. Epub 2014 Feb 12.
5
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.骨髓增殖性肿瘤体细胞突变的克隆进化及其临床相关性。
Blood. 2014 Apr 3;123(14):2220-8. doi: 10.1182/blood-2013-11-537167. Epub 2014 Jan 29.
6
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.伴有未突变 JAK2 的骨髓增殖性肿瘤中的体细胞 CALR 突变。
N Engl J Med. 2013 Dec 19;369(25):2391-2405. doi: 10.1056/NEJMoa1312542. Epub 2013 Dec 10.
7
Dnmt3a is essential for hematopoietic stem cell differentiation.DNMT3A 对于造血干细胞的分化是必不可少的。
Nat Genet. 2011 Dec 4;44(1):23-31. doi: 10.1038/ng.1009.
8
Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia.治疗相关性和继发性急性髓系白血病中体细胞 DNMT3A 突变的频率、发病机制和临床影响。
Haematologica. 2012 Feb;97(2):246-50. doi: 10.3324/haematol.2011.051581. Epub 2011 Oct 11.
9
Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice.TET2 基因的十十一易位 2 负向调控了小鼠造血干细胞的自我更新和分化。
Proc Natl Acad Sci U S A. 2011 Aug 30;108(35):14566-71. doi: 10.1073/pnas.1112317108. Epub 2011 Aug 22.
10
Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patient.一名慢性期真性红细胞增多症患者体细胞DNMT3A和JAK2突变的克隆及谱系分析
Br J Haematol. 2012 Jan;156(2):268-70. doi: 10.1111/j.1365-2141.2011.08837.x. Epub 2011 Aug 22.
Zotero 插件